News
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027.
Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...
Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Texas Attorney General Ken Paxton alleges that Eli Lilly bribed Texas medical providers to provide the company's drugs. Eli Lilly denies the claims.
Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback